Loading...
CSL logo

CSL LimitedASX:CSL Rapport sur les actions

Capitalisation boursière AU$72.3b
Prix de l'action
AU$150.01
Indisponible
1Y-41.6%
7D-16.9%
Valeur du portefeuille
​
Voir

CSL Limited

ASX:CSL Rapport sur les actions

Capitalisation boursière : AU$72.3b

CSL (CSL) Aperçu de l'action

CSL Limited se consacre à la recherche, au développement, à la fabrication, à la commercialisation et à la distribution de produits biopharmaceutiques et de vaccins en Australie, aux États-Unis, en Allemagne, au Royaume-Uni, en Suisse, en Chine, à Hong Kong et dans le monde entier. Plus de détails

CSL analyse fondamentale
Score flocon de neige
Évaluation4/6
Croissance future3/6
Performances passées1/6
Santé financière4/6
Dividendes4/6

Récompenses

Se négocie à 48.8% en dessous de notre estimation de sa juste valeur

Les bénéfices devraient augmenter 29.7% par an

Les analystes s'accordent à dire que le prix des actions augmentera de 40.6%

Analyse des risques

A un niveau d'endettement élevé

Le dividende de 2.75% n'est pas bien couvert par les bénéfices

Des éléments non récurrents importants ayant un impact sur les résultats financiers

Les marges bénéficiaires (9.1%) sont inférieures à celles de l'année dernière (18%)


CSL Community Fair Values

Create Narrative

See what 317 others think this stock is worth. Follow their fair value or set your own to get alerts.

CSL logo
CSL

Seqirus Demerger And Cost Savings Will Shape A Steady Long Term Outlook

Catalysts About CSL CSL is a global biopharmaceutical group focused on plasma therapies, vaccines and specialty medicines addressing rare and serious diseases. What are the underlying business or industry changes driving this perspective?
View narrative
AU$180.87
FV
17.1% sous-évalué décote intrinsèque
2.87%
Revenue growth p.a.
328
users have viewed this narrative
0users have liked this narrative
0users have commented on this narrative
6users have followed this narrative
CSL logo
CSL

CSL: Share Price Correction Will Present Opportunity As Vaccine Uncertainty Eases

Key Takeaways Operational transformation and investment in innovation are expected to drive margin expansion, earnings growth, and faster introduction of high-value therapies. Market expansion, a focused business structure, and strong demand for plasma and specialty products support sustainable top-line growth and premium positioning.
View narrative
AU$228.58
FV
34.4% sous-évalué décote intrinsèque
4.16%
Revenue growth p.a.
2.3k
users have viewed this narrative
2users have liked this narrative
0users have commented on this narrative
150users have followed this narrative
CSL logo
CSL

CSL will thrive with an 18% profit surge ahead

this is spam this is spam this is spam this is spam this is spam this is spam this is spam this is spam this is spam this is spam this is spam this is spam this is spam this is spam this is spam this is spam this is spam this is spam this is spam this is spam this is spam this is spam this is spam this is spam this is spam this is spam this is spam this is spam this is spam this is spam this is spam this is spam this is spam this is spam this is spam this is spam this is spam this is spam this is spam this is spam this is spam this is spam this is spam this is spam this is spam this is spam this is spam this is spam this is spam this is spam this is spam this is spam this is spam this is spam this is spam this is spam this is spam this is spam this is spam this is spam this is spam this is spam this is spam this is spam this is spam this is spam this is spam this is spam this is spam this is spam this is spam this is spam this is spam this is spam this is spam this is spam this is spam this is spam this is spam this is spam this is spam this is spam this is spam this is spam this is spam this is spam this is spam this is spam this is spam this is spam this is spam this is spam this is spam this is spam this is spam this is spam this is spam this is spam this is spam this is spam this is spam this is spam this is spam this is spam this is spam this is spam this is spam this is spam this is spam this is spam this is spam this is spam this is spam this is spam this is spam this is spam this is spam this is spam this is spam this is spam this is spam this is spam this is spam this is spam this is spam this is spam this is spam this is spam this is spam this is spam this is spam this is spam this is spam this is spam this is spam this is spam this is spam this is spam this is spam this is spam this is spam this is spam this is spam this is spam this is spam this is spam this is spam this is spam this is spam this is spam this is spam this is spam this is spam this is spam this is spam this is spam this is spam this is spam this is spam this is spam this is spam this is spam this is spam this is spam this is spam this is spam this is spam this is spam this is spam this is spam this is spam this is spam this is spam this is spam this is spam this is spam this is spam this is spam this is spam this is spam this is spam this is spam this is spam this is spam this is spam this is spam this is spam this is spam this is spam this is spam this is spam this is spam this is spam this is spam this is spam this is spam this is spam this is spam this is spam this is spam this is spam this is spam this is spam this is spam this is spam this is spam this is spam this is spam this is spam this is spam this is spam this is spam this is spam this is spam this is spam this is spam this is spam this is spam this is spam this is spam this is spam this is spam this is spam this is spam this is spam this is spam this is spam this is spam this is spam this is spam this is spam this is spam this is spam this is spam this is spam this is spam this is spam this is spam this is spam this is spam this is spam this is spam this is spam this is spam this is spam this is spam this is spam this is spam this is spam this is spam this is spam this is spam this is spam this is spam this is spam this is spam this is spam this is spam this is spam this is spam this is spam this is spam this is spam this is spam this is spam this is spam this is spam this is spam this is spam this is spam this is spam this is spam this is spam this is spam this is spam this is spam this is spam this is spam this is spam this is spam this is spam this is spam this is spam this is spam this is spam this is spam this is spam this is spam this is spam this is spam this is spam this is spam this is spam this is spam this is spam this is spam this is spam this is spam this is spam this is spam this is spam this is spam this is spam this is spam this is spam this is spam this is spam this is spam this is spam this is spam this is spam this is spam this is spam this is spam this is spam this is spam this is spam this is spam this is spam this is spam this is spam this is spam this is spam this is spam this is spam this is spam this is spam this is spam this is spam this is spam this is spam this is spam this is spam this is spam this is spam this is spam this is spam this is spam this is spam this is spam this is spam this is spam this is spam this is spam this is spam this is spam this is spam this is spam this is spam this is spam this is spam this is spam this is spam this is spam this is spam this is spam this is spam this is spam this is spam this is spam this is spam this is spam this is spam this is spam this is spam this is spam this is spam this is spam this is spam this is spam this is spam this is spam this is spam this is spam this is spam this is spam this is spam this is spam
View narrative
AU$239.81
FV
37.4% sous-évalué décote intrinsèque
6.48%
Revenue growth p.a.
77
users have viewed this narrative
0users have liked this narrative
0users have commented on this narrative
4users have followed this narrative
CSL logo
CSL

Margin Recovery And Operating Model Simplification Will Support A Stronger Long Term Outlook

Catalysts About CSL CSL is a global biopharmaceutical group focused on plasma derived therapies, vaccines and specialty medicines for rare and serious diseases. What are the underlying business or industry changes driving this perspective?
View narrative
AU$289.37
FV
48.2% sous-évalué décote intrinsèque
5.76%
Revenue growth p.a.
365
users have viewed this narrative
0users have liked this narrative
0users have commented on this narrative
1users have followed this narrative
View Stock Community
UNCY logo
Unicycive Therapeutics

Looking to be second time lucky with a game-changing new product

Key Takeaways Unicycive has successfully completed clinical development of its lead asset, Oxylanthanum Carbonate (OLC). OLC has been designed to improve on current phosphate binders by offering better efficacy, fewer pills, and improved tolerability over alternative treatments for hyperphosphatemia chronic kidney disease patients on dialysis.Read more

View narrative
1.4k
users have viewed this narrative
5users have liked this narrative
0users have commented on this narrative
28users have followed this narrative
US$21.53
71.2% sous-évalué décote intrinsèque
stuart_roberts's Fair Value
Profit Margin
20%
Future PE
27x
Price in 2030
US$34.67

CSL Limited Concurrents

Historique des prix et performances

Résumé des hausses, des baisses et des variations du cours de l'action pour la période du 1er janvier au 31 décembre 2009 CSL
Historique des cours de bourse
Prix actuel de l'actionAU$150.01
Plus haut sur 52 semainesAU$275.79
Plus bas sur 52 semainesAU$150.00
Bêta0.28
Variation sur 1 mois-14.54%
Variation sur 3 mois-16.86%
Variation sur 1 an-41.61%
Variation sur 3 ans-49.73%
Variation sur 5 ans-45.34%
Évolution depuis l'introduction en bourse18,651.44%

Nouvelles et mises à jour récentes

Seqirus Demerger And Cost Savings Will Shape A Steady Long Term Outlook

Catalysts About CSL CSL is a global biopharmaceutical group focused on plasma therapies, vaccines and specialty medicines addressing rare and serious diseases. What are the underlying business or industry changes driving this perspective?

Recent updates

Seqirus Demerger And Cost Savings Will Shape A Steady Long Term Outlook

Catalysts About CSL CSL is a global biopharmaceutical group focused on plasma therapies, vaccines and specialty medicines addressing rare and serious diseases. What are the underlying business or industry changes driving this perspective?

CSL Limited's (ASX:CSL) Share Price Not Quite Adding Up

Sep 25
CSL Limited's (ASX:CSL) Share Price Not Quite Adding Up

Is CSL Limited (ASX:CSL) Trading At A 43% Discount?

Aug 07
Is CSL Limited (ASX:CSL) Trading At A 43% Discount?

Here's Why CSL (ASX:CSL) Can Manage Its Debt Responsibly

Jun 14
Here's Why CSL (ASX:CSL) Can Manage Its Debt Responsibly

Weekly Picks: 🧠 Alphabet’s AI edge, CSL’s pricing power, and a chip underdog

Apr 16
Weekly Picks: 🧠 Alphabet’s AI edge, CSL’s pricing power, and a chip underdog

CSL is undervalued in High Tax Scenario

CSL Behring: This is CSL's largest segment and the global leader (#1) in plasma therapies within an estimated US$30 billion industry.11 It focuses on researching, developing, manufacturing, and distri
User avatar

Advancements In iNOMi Technology And HEMGENIX Will Strengthen Market Position

Advancements in plasma collection and operational efficiencies are set to reduce costs and improve CSL Behring's margins, potentially boosting overall earnings.

Rendement pour les actionnaires

CSLAU BiotechsAU Marché
7D-16.9%-15.2%2.0%
1Y-41.6%-41.4%3.0%

Rendement vs Industrie: CSL correspondait au secteur Australian Biotechs qui a rapporté -41.4 % au cours de l'année écoulée.

Rendement vs marché: CSL a sous-performé le marché Australian qui a rapporté 3 % au cours de l'année écoulée.

Volatilité des prix

Is CSL's price volatile compared to industry and market?
CSL volatility
CSL Average Weekly Movement3.8%
Biotechs Industry Average Movement11.0%
Market Average Movement9.5%
10% most volatile stocks in AU Market17.8%
10% least volatile stocks in AU Market3.6%

Cours de l'action stable: CSL n'a pas connu de volatilité de prix significative au cours des 3 derniers mois par rapport au marché Australian.

Volatilité au fil du temps: La volatilité hebdomadaire de CSL ( 4% ) est restée stable au cours de l'année écoulée.

À propos de l'entreprise

FondéeSalariésPDGSite web
191629,904Gordon Naylorwww.csl.com

CSL Limited se consacre à la recherche, au développement, à la fabrication, à la commercialisation et à la distribution de produits biopharmaceutiques et de vaccins en Australie, aux États-Unis, en Allemagne, au Royaume-Uni, en Suisse, en Chine, à Hong Kong et dans le monde entier. La société opère par le biais des segments CSL Behring, CSL Seqirus et CSL Vifor. Le segment CSL Behring fabrique, commercialise et distribue des produits plasmatiques, des thérapies géniques et des recombinants.

CSL Limited Résumé des fondamentaux

Comment les bénéfices et les revenus de CSL se comparent-ils à sa capitalisation boursière ?
CSL statistiques fondamentales
Capitalisation boursièreAU$72.31b
Bénéfices(TTM)AU$1.97b
Recettes(TTM)AU$21.78b
36.6x
Ratio P/E
3.3x
Ratio P/S

Le site CSL est-il surévalué ?

Voir Juste valeur et analyse de l'évaluation

Bénéfices et recettes

Principales statistiques de rentabilité tirées du dernier rapport sur les bénéfices (TTM)
CSL compte de résultat (TTM)
RecettesUS$15.41b
Coût des recettesUS$7.42b
Marge bruteUS$7.99b
Autres dépensesUS$6.60b
Les revenusUS$1.40b

Derniers bénéfices déclarés

Dec 31, 2025

Prochaine date de publication des résultats

Aug 18, 2026

Résultat par action (EPS)2.90
Marge brute51.87%
Marge bénéficiaire nette9.06%
Ratio dettes/capitaux propres46.7%

Quelles ont été les performances à long terme de CSL?

Voir les performances historiques et les comparaisons

Dividendes

2.8%
Rendement actuel des dividendes
101%
Ratio de distribution

Analyse de l'entreprise et données financières

DonnéesDernière mise à jour (heure UTC)
Analyse de l'entreprise2026/02/15 05:38
Cours de l'action en fin de journée2026/02/13 00:00
Les revenus2025/12/31
Revenus annuels2025/06/30

Sources de données

Les données utilisées dans notre analyse de l'entreprise proviennent de S&P Global Market Intelligence LLC. Les données suivantes sont utilisées dans notre modèle d'analyse pour générer ce rapport. Les données sont normalisées, ce qui peut entraîner un délai avant que la source ne soit disponible.

PaquetDonnéesCadre temporelExemple de source américaine *
Finances de l'entreprise10 ans
  • Compte de résultat
  • Tableau des flux de trésorerie
  • Bilan
Estimations consensuelles des analystes+3 ans
  • Prévisions financières
  • Objectifs de prix des analystes
Prix du marché30 ans
  • Cours des actions
  • Dividendes, scissions et actions
Propriété10 ans
  • Actionnaires principaux
  • Délits d'initiés
Gestion10 ans
  • L'équipe dirigeante
  • Conseil d'administration
Principaux développements10 ans
  • Annonces de l'entreprise

* Exemple pour les titres américains ; pour les titres non américains, des formulaires réglementaires et des sources équivalentes sont utilisés.

Sauf indication contraire, toutes les données financières sont basées sur une période annuelle mais mises à jour trimestriellement. C'est ce qu'on appelle les données des douze derniers mois (TTM) ou des douze derniers mois (LTM). En savoir plus.

Modèle d'analyse et flocon de neige

Les détails du modèle d'analyse utilisé pour générer ce rapport sont disponibles sur notre page Github. Nous avons également des guides sur la façon d'utiliser nos rapports et des tutoriels sur Youtube.

Découvrez l'équipe de classe mondiale qui a conçu et construit le modèle d'analyse Simply Wall St.

Indicateurs de l'industrie et du secteur

Nos indicateurs de secteur et de section sont calculés toutes les 6 heures par Simply Wall St. Les détails de notre processus sont disponibles sur Github.

Sources des analystes

CSL Limited est couverte par 26 analystes. 16 de ces analystes ont soumis les estimations de revenus ou de bénéfices utilisées comme données d'entrée dans notre rapport. Les soumissions des analystes sont mises à jour tout au long de la journée.

AnalysteInstitution
Saul HadassinBarrenjoey Markets Pty Limited
Thomas WakimBell Potter
Lyanne HarrisonBofA Global Research